- CureVac, a German biotech backed by Bill Gates, said Thursday it is in talks with the EU to supply 225 million doses of its potential coronavirus vaccine.
- Shares of CureVac jumped more than 18% in premarket trading on Thursday.
- If an agreement is reached, it would mark the company’s first bilateral supply deal, according to Reuters.
- Watch CureVac trade live on Markets Insider.
- Read more on Business Insider.
Shares of CureVac, a German biotech firm backed by Bill Gates, surged as much as 18% in premarket trading Thursday after the company said it is in talks with the European Commission to supply doses of its potential coronavirus vaccine.
The potential contract with the European Commission intends to provide European Union member states with up to 225 million doses of the coronavirus vaccine, once it has been proven safe and effective against COVID-19, the company said in a press release.
The contract would also give the European Commission the option to purchase an additional 180 million doses, bringing the total to 405 million doses of the potential vaccine.
If an agreement is reached, it would mark the company’s first bilateral supply deal, according to Reuters.
CureVac’s mRNA-based COVID-19 vaccine candidate is currently in a Phase 1 clinical trial at different sites in Germany and Belgium, aiming to determine safety and efficacy of the drug in humans, the company said. It expects to have results from the trial early in the fourth quarter of 2020, and move to the next phase soon after.
Business Insider Emails & Alerts
Site highlights each day to your inbox.